CRP and chronic kidney disease: Recently, ziltivikimab, an IL‐6 inhibiting monoclonal antibody, has been tested in the RESCUE trial amongst participants with moderate to severe chronic kidney disease and an hs‐CRP levels of > 2.0 mg/L, where treatment for 12 weeks resulted in 77%–92% reduction in the median CRP levels [82].